Novartis Korea said it held the seventh emotional support program, CHEERYOU, for patients with rare and intractable diseases in collaboration with the Korean Organization for Rare Diseases (KORD) at the Pine Valley Glamping Site in Pocheon, Gyeonggi Province, last Friday.The CHEERYOU campaign, a fla
ST Pharm said it has taken its first step towards becoming the global leader in the oligonucleotide contract development and manufacturing organization (CDMO) domain with the groundbreaking ceremony for its second oligonucleotide facility on Monday.The new plant will be located in Ansan, Gyeonggi Pr
As Korean and foreign pharmaceutical and biotechnology companies are stepping up to develop antibody-drug conjugates (ADCs), Daiichi Sankyo presented its outlook on the future direction of ADC development.Daiichi Sankyo co-developed Enhertu (trastuzumab deruxtecan), a new generation ADC anticancer d
PharmAbcine received approval from the Australian Human Research Ethics Committees (HRECs) last Friday to conduct a phase 1a/b clinical trial of PMC-309.PMC-309 is a VISTA-targeted immuno-oncology agent for patients with advanced or metastatic solid tumors.According to PharmAbcine, PMC-309 is an IgG
Sanofi Aventis Korea is aiming to revolutionize the treatment landscape for Pompe disease patients with the reimbursement of its novel enzyme replacement therapy, Nexviazyme (ingredient: avalglucosidase alfa-ngpt), from Sep. 1, the company said.Sanofi-Aventis Korea organized a press conference at th
In the wake of revelations that a key ingredient could transform into tumor-inducing kidney cells, Kolon Life Science's osteoarthritis gene therapy, Invossa-K Inj., which had its product license revoked, has been linked to numerous reported cases of tumors in patients after administration.According
Climate change has had widespread impacts on the planet and its consequences to human health are escalating, presenting challenges for vaccine manufacturers, researchers, and epidemiologists alike. Dr. Adamberage Ruklanthi de Alwis, Deputy Director of the Center for Outbreak Preparedness at Duke-NUS
Moderna announced its collaboration with Korea University Medical Center and Chosun University Industry-Academic Cooperation Foundation on Friday to expand its global public health initiative, mRNA Access, in Korea.The initiative aims to expedite the vaccine development process worldwide using Moder
Daewoong Therapeutics, an affiliate of the Daewoong Group, said on Friday that it received approval from the Ministry of Food and Drug Safety (MFDS) for a phase 1 clinical trial plan for its diabetic retinopathy candidate, DWRX2008. DWRX2008 is a diabetic retinopathy treatment that Daewoong Therapeu
A local doctor expressed his enthusiasm that the reimbursement of Pfizer Korea's Ngenla (ingredient: Somatropin), a once-weekly growth hormone drug, will enhance compliance among adolescent patients.At a press conference held to mark the reimbursement at the Koreana Hotel in Seoul on Thursday, Profe
Hanmi Pharm has suggested that the company could develop HM15912, its short bowel syndrome treatment candidate developed as a once-monthly dosage form, as a treatment for another rare disease, graft-versus-host disease (GVHD).Hanmi said Thursday that it presented two posters on the research results
SINGAPORE -- The International Association for the Study of Lung Cancer 2023 World Congress of Lung Cancer (IASLC 2023 WCLC), held Sept. 9-12 in Singapore, featured many milestone studies in treating lung cancer.AstraZeneca showed a particularly remarkable performance.Its Tagrisso (osimertinib), a t
CHA Vaccine Institute said on Thursday it has obtained a Canadian patent for its Lipo-pam immune enhancer, recognizing it as an adjuvant for vaccines that include a liposome with the lipopeptide as the active ingredient.The patent covers both the vaccine and the associated method for manufacturing v
Gilead Sciences said it has appointed Choi Jae-yeon, the former Managing Director of MSD Taiwan, as the new general manager of its Korea offshoot.Choi will oversee Gilead's operations in Korea, with a focus on developing business in areas such as HIV, viral hepatitis, Covid-19, antifungal treatments
Korean pharmaceutical companies have received a heap of administrative penalties from the Ministry of Food and Drug Safety (MFDS), causing a stir.On Monday, GC Wellbeing, a subsidiary of the GC Group, received a one-month suspension of manufacturing four specialized drugs from the MFDS. As a result,
Hanmi Science said on Wednesday that it plans to pursue obesity management as a strong growth engine to build a unique portfolio called, the "Hanmi Obesity Pipeline (H.O.P)."Recently, Danish biotech company Novo Nordisk has gained significant media attention for its weight loss drug, Wegovy (ingredi
AriBio, a biotech firm specializing in medicines for neurodegenerative and infectious disease, said Wednesday it has signed a memorandum of understanding for strategic collaboration with Shanghai Pharmaceuticals, the second-largest pharmaceutical distributor in China.The main contents of the MOU inc
Samsung Biologics said on Wednesday that Samsung Life Science Fund made an equity investment in AIMEDBIO, a domestic company specializing in therapeutic solutions for neuro-oncological and neuro-degenerative diseases.This marks the fund’s fourth investment after previous investments in foreign compa
VaxCell Biotherapeutics said it reported an impressive disease control rate (DCR) of “100 percent” for combination therapy using VAX-NK, its hepatocellular carcinoma (HCC) treatment candidate, and hepatic arterial infusion chemotherapy (HAIC), from its phase 2a trial.Speaking at a press conference a
The Seoul Administrative Court has set a date for the verdict in the lawsuit between the Ministry of Food and Drug Safety (MFDS) and PharmaResearchBio regarding the latter's claims to cancel the MFDS' order to recall, destroy, and halt its botulinum toxin (BTX) product.The court will make the ruling